Study Summary
This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of CD19 CARvac in patients with relapsed and/or refractory B cell malignancies.
Want to learn more about this trial?
Request More InfoInterventions
CD19 CARvac T cellsBIOLOGICAL
CD19 CARvac T cells administered to patients, will be either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| The General Hospital of Western Theater Command | Chengdu | China | |
| Peking University Shenzhen Hospital | Shenzhen | China |